Feasibility, Efficacy, and Safety of Peripheral Venous Access for Chronic Double-Filtration Plasmapheresis with Regional Citrate Anticoagulation
Blood Purification · 2023
DOI: 10.1159/000531688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Purification, 2023. Verfasst von Antoine Cardinale und 4 weiteren Autor:innen. Beteiligte Einrichtung: Service Néphrologie-Dialyse-Aphérèse, CHU Nîmes, Nîmes, France. Hauptthemen laut MEDLINE: Citric Acid, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
Peripheral venous access (PVA) is recommended as a first-line vascular approach for therapeutic plasmapheresis with centrifugation methods but not filtration, which usually requires high blood flow. We evaluated the feasibility, efficacy, and safety of double-filtration plasmapheresis (DFPP) with PVA, using ultrasound guidance and regional citrate anticoagulation (RCA), i.e., PVA-RCA-DFPP in patients undergoing chronic DFPP. Secondly, we assessed the number of central venous catheters (CVCs) avoided.
Methods
A single-center retrospective study evaluated 22 adult patients on chronic DFPP to perform PVA-RCA-DFPP. They were classified into 3 groups: successful (i.e., completion of sessions with PVA), primary failure (i.e., no sessions completed), secondary failure (i.e., ≥1 session with PVA completed but secondary return with CVC or arteriovenous fistula).
Results
Among the 22 patients included (64% men), 7 patients (32%) were classified as primary failures (2 patient refusals, 5 inadequate PVAs), 1 patient (5%) as a secondary failure (due to uncomfortable venipunctures), and 14 patients (64%) as successful. In the successful group including 12 patients treated for chronic inflammatory demyelinating polyneuropathy (CIDP) and 2 patients for familial hypercholesterolemia (FH) (2 patients), 116 sessions were performed, with a median treated plasma volume of 4.3 L [IQR 3.6–4.6] (45 mL/kg) for a median duration of 134 min [IQR 122–144], and a median blood flow of 94 mL/min [IQR 87–103]. For the CIDP group, 90% of sessions achieved a plasma volume >1 TPV, and for the FH group 91% of sessions achieved an LDLc reduction >60%. Eleven sessions out of 116 (9%) were interrupted, mostly due to PVA dysfunction (5/11) and circuit clotting (4/11). Session interruptions decreased significantly between each patient’s first and following sessions (29% to 7%, p = 0.009).
Conclusion
Chronic PVA-RCA-DFPP can be performed safely and efficiently, avoiding the use of CVCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service Néphrologie-Dialyse-Aphérèse, CHU Nîmes, Nîmes, France.
- IDESP UMR, Montpellier, France.
Zitieren
APA
Cardinale, A., Pambrun, E., Prelipcean, C., Messikh, Z., & Moranne, O. (2023). Feasibility, Efficacy, and Safety of Peripheral Venous Access for Chronic Double-Filtration Plasmapheresis with Regional Citrate Anticoagulation. Blood Purification. https://doi.org/10.1159/000531688
Vancouver
Cardinale A, Pambrun E, Prelipcean C, Messikh Z, Moranne O. Feasibility, Efficacy, and Safety of Peripheral Venous Access for Chronic Double-Filtration Plasmapheresis with Regional Citrate Anticoagulation. Blood Purification. 2023. doi:10.1159/000531688
BibTeX
@article{Cardinale2023,
author = {Cardinale, Antoine and Pambrun, Emilie and Prelipcean, Camelia and Messikh, Ziyad and Moranne, Olivier},
title = {Feasibility, Efficacy, and Safety of Peripheral Venous Access for Chronic Double-Filtration Plasmapheresis with Regional Citrate Anticoagulation},
journal = {Blood Purification},
year = {2023},
doi = {10.1159/000531688}
}
EUVIMED